Clinical Trials & Pipeline
Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of leading microRNA-based oncology therapeutics, the first to demonstrate clinical proof of concept for microRNA replacement therapy.
LEARN MORE ABOUT US
MRX34, Mirna’s lead product candidate, is the first microRNA mimic to enter clinical testing.
LEARN MORE ABOUT OUR CLINICAL TRIALS AND PIPELINE
September 20, 2016
Mirna Therapeutics Halts Phase 1 Clinical Study of MRX34
August 31, 2016
Mirna Therapeutics to Participate in Two Healthcare Investor Conferences in September
VIEW ALL NEWS
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.